The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris

Journal of the American Academy of Dermatology

Volumn 43, Issue 6, 2000, Pages 1058-1064

  Turner, Matthew S ^c   Sutton, David ^a   Sauder, Daniel N ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 0033669732     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.109297     Document Type: Article

References (30)

1. Pemphigus: Epidemiologic and survival characteristics of 59 patients, 1955-1973
2. Pemphigus: A 20-year review of 107 patients treated with corticosteroids
3. Pemphigus: A 20-year survey of experience with 70 cases
4. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy
5. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum
6. An organ culture model for the study of pemphigus acantholysis
7. The pathogenic role of pemphigus antibodies and proteinase in epidermal acantholysis
8. The extracellular aminoterminal domain of bovine desmoglein 1 (Dsg1) is recognized only by certain pemphigus foliaceus sera, whereas its intracellular domain is recognized by both pemphigus vulgaris and pemphigus foliaceus sera
9. Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular, domain of the pemphigus vulgaris antigen (desmoglein 3)
10. Organ culture studies of pemphigus antibodies. II. Ultrastructural comparison between acantholytic changes in vitro and human pemphigus lesions
11. Epidermal acantholysis induced in vitro by pemphigus autoantibody: An ultrastructural study
12. Some factors affecting prognosis in pemphigus vulgaris and pemphigoid
13. Management of the immunobullous disorders. II. Pemphigus
14. Treatment of pemphigus
15. Death in pemphigus
16. The treatment of pemphigus vulgaris: Experience with 48 patients seen over an 11-year period
17. Influence of treatment on the clinical course of pemphigus vulgaris
18. Adjuvant therapy of pemphigus
19. The steroid-sparing effect of long-term plasmapheresis in pemphigus
20. Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical uses
21. Detection of cross-reactive idiotypes in the serum of patients with bullous pemphigoid
22. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis
23. Plasma exchange in the treatment of pemphigus vulgaris
24. Plasma exchange in pemphigus: Uncontrolled study of ten patients
25. Dexamethasonecyclophosphamide pulse therapy for pemphigus
26. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide
27. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris
28. The usefulness of immunofluorescent tests in pemphigus patients in clinical remission
29. Pemphigus in remission: Value of negative direct immunofluorescence in management
30. Metabolism of immunoglobulins